 <h1>Ivacaftor / lumacaftor Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ivacaftor/lumacaftor include:</b> upper respiratory tract infection, dyspnea, chest discomfort, nausea, and skin rash. <b>Other side effects include:</b> influenza, and flatulence.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ivacaftor / lumacaftor: oral granule, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ivacaftor / lumacaftor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ivacaftor / lumacaftor:</p><p>
<i>More common</i>
</p><ul>
<li>Difficult or labored breathing</li>
<li>tightness in the chest</li>
<li>upper abdominal or stomach pain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>dark urine</li>
<li>discomfort in the upper right stomach area</li>
<li>dizziness</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>stomach pain, continuing</li>
<li>unusual tiredness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ivacaftor / lumacaftor may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>bloated feeling</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>cough producing mucus</li>
<li>cramps</li>
<li>diarrhea</li>
<li>ear congestion</li>
<li>excess air or gas in the stomach or bowels</li>
<li>feeling of fullness</li>
<li>fever</li>
<li>heavy bleeding</li>
<li>increased sputum production</li>
<li>longer or heavier menstrual periods</li>
<li>loss of voice</li>
<li>muscle aches</li>
<li>passing gas</li>
<li>rash</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stopping of menstrual bleeding</li>
<li>stuffy or runny nose</li>
<li>unusual weakness</li>
</ul><p>
<!-- end oral granule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivacaftor / lumacaftor: oral granule for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects were dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, respiration abnormal, blood creatine phosphokinase increased, rash, flatulence, rhinorrhea, and influenza.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Infective pulmonary exacerbation of cystic fibrosis (37.5%), cough (30.5%), sputum increased (14.8 %), dyspnea (up to 14%), hemoptysis (13.8%), nasopharyngitis (up to 13%), upper respiratory tract infection (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Rhinitis, pharyngeal erythema, sinus congestion, respiration abnormal, rhinorrhea, nasal congestion</p>
<p></p>
<p>Ivacaftor:</p>
<p><b>Very common</b> (10% or more): Nasopharyngitis, nasal congestion</p>
<p><b>Common</b> (1% to 10%): Sinus congestion, pharyngeal erythema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 13%), diarrhea (up to 12%), abdominal pain</p>
<p><b>Common</b> (1% to 10%): Flatulence, oropharyngeal pain, vomiting</p>
<p></p>
<p>Ivacaftor:</p>
<p><b>Very common</b> (10% or more): Abdominal pain<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 15.7%), dizziness</p>
<p></p>
<p>Ivacaftor:</p>
<p><b>Very common</b> (10% or more): Dizziness, headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Bacteria in sputum</p>
<p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased, fatigue, influenza, ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, vestibular disorder, chest discomfort</p>
<p><b>Uncommon</b> (0.1% to 1%): Ear congestion</p>
<p></p>
<p>Ivacaftor:</p>
<p><b>Very common</b> (10% or more): Bacteria in sputum</p>
<p><b>Common</b> (1% to 10%): Ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, vestibular disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Ear congestion<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Breast mass</p>
<p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain</p>
<p></p>
<p>Ivacaftor:</p>
<p><b>Common</b> (1% to 10%): Breast mass</p>
<p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Blood pressure increased/hypertension<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): AST increased, ALT increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic encephalopathy, cholestatic hepatitis</p>
<p><b>Frequency not reported</b>: Total bilirubin increased</p>
<p><b>Postmarketing reports</b>: Liver failure leading to death, liver function decompensation<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstruation abnormal/irregular, dysmenorrhea, metrorrhagia, amenorrhea, menorrhagia</p>
<p><b>Uncommon</b> (0.1% to 1%): Oligomenorrhea, polymenorrhea<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Non-congenital lens opacities<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Symdeko and Orkambi?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about ivacaftor / lumacaftor</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: CFTR combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lumacaftor and ivacaftor &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Orkambi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivacaftor / lumacaftor: oral granule for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects were dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, respiration abnormal, blood creatine phosphokinase increased, rash, flatulence, rhinorrhea, and influenza.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Infective pulmonary exacerbation of cystic fibrosis (37.5%), cough (30.5%), sputum increased (14.8 %), dyspnea (up to 14%), hemoptysis (13.8%), nasopharyngitis (up to 13%), upper respiratory tract infection (up to 10%)</p><p><b>Common</b> (1% to 10%): Rhinitis, pharyngeal erythema, sinus congestion, respiration abnormal, rhinorrhea, nasal congestion</p><p></p><p>Ivacaftor:</p><p><b>Very common</b> (10% or more): Nasopharyngitis, nasal congestion</p><p><b>Common</b> (1% to 10%): Sinus congestion, pharyngeal erythema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 13%), diarrhea (up to 12%), abdominal pain</p><p><b>Common</b> (1% to 10%): Flatulence, oropharyngeal pain, vomiting</p><p></p><p>Ivacaftor:</p><p><b>Very common</b> (10% or more): Abdominal pain<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 15.7%), dizziness</p><p></p><p>Ivacaftor:</p><p><b>Very common</b> (10% or more): Dizziness, headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Bacteria in sputum</p><p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased, fatigue, influenza, ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, vestibular disorder, chest discomfort</p><p><b>Uncommon</b> (0.1% to 1%): Ear congestion</p><p></p><p>Ivacaftor:</p><p><b>Very common</b> (10% or more): Bacteria in sputum</p><p><b>Common</b> (1% to 10%): Ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, vestibular disorder</p><p><b>Uncommon</b> (0.1% to 1%): Ear congestion<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Breast mass</p><p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain</p><p></p><p>Ivacaftor:</p><p><b>Common</b> (1% to 10%): Breast mass</p><p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Blood pressure increased/hypertension<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): AST increased, ALT increased</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic encephalopathy, cholestatic hepatitis</p><p><b>Frequency not reported</b>: Total bilirubin increased</p><p><b>Postmarketing reports</b>: Liver failure leading to death, liver function decompensation<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstruation abnormal/irregular, dysmenorrhea, metrorrhagia, amenorrhea, menorrhagia</p><p><b>Uncommon</b> (0.1% to 1%): Oligomenorrhea, polymenorrhea<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Non-congenital lens opacities<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Symdeko and Orkambi?</li>
</ul><h2>More about ivacaftor / lumacaftor</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: CFTR combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lumacaftor and ivacaftor &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>